Senju Pharmaceutical Co., Ltd.

Other

Mitsubishi Tanabe Pharma Corporation

Mitsubishi Pharma Corporation

Itoham Foods Inc.

Yukuo Yoshida

Mitsuyoshi Azuma

Masayoshi Uehata

Yuji Sakamoto

Jun Inoue

Mitsunori Waki

Yoshiko Takayama

Kazuhisa Kashimoto

Satomi Onoue

Yoko Minagawa

Atsuko Fujii

The present invention provides a visual function disorder improving agent containing a compound having Rho kinase inhibitory activity, particularly (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide, as an effective component. This agent has axon of the retinal ganglion cellal extension promoting action and optic nerve cell regeneration promoting action, and is useful for the treatment of a visual function disorder associated with various eye diseases caused by damage, defects, degeneration and the like in the retinal or optic nerve.

Visual function disorder improving agents

Remedies for dry eye and diseases associated with dry eye which contain as the active ingredient peptides represented by the general formula (I):H-His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-X-Gln-X-Ala-Val-X-X-Tyr-Leu-X-X(SEQ ID NOS: 26-36) &#x2003;&#x2003;(I)wherein X, Xand Xrepresent Lys or Arg, respectively; Xrepresents Met, Leu or nLeu; Xrepresents a chemical bond, Asn, Asn-Ser, Asn-Ser-Ile, Asn-Ser-Ile-Leu(SEQ ID NO: 37) or Asn-Ser-Ile-Leu-Asn-X(SEQ ID NOS: 38-43) (wherein Xrepresents a chemical bond, Gly, etc.); and Xrepresents &#x2014;OH or &#x2014;NH, or pharmaceutically acceptable salts thereof:.

Remedies for dry eye and diseases associated with dry eye

Preventives/remedies for glaucoma

Agent for prophylaxis and treatment of glaucoma

A pharmaceutical composition for the prophylaxis and therapy of a disease arising from ocular fundus tissue cytopathy such as retinochoroidal disease, glaucoma, and posterior complication arising form photocoagulation, which contains, as an active ingredient, a compound of formula (I) wherein R represents an alkyl group having 1 to 4 carbon atoms or an aryl group having 6 to 10 carbon atoms which is optionally substituted; R and R may be the same or different and each represents hydrogen or an alkyl group having 1 to 4 carbon atoms or R and R may jointly form a ring having 3 to 7 carbon atoms; and R represents a lower alkyl group which substituted by aryl, cycloalkyl, or aromatic heterocyclic residue, or a pharmaceutically acceptable salt thereof.

Pharmaceutical composition for prophylaxis and therapy of diseases associated with ocular fundus tissue cytography

Pharmaceutical composition containing a cysteine protease inhibitor for prophylaxis and therapy of brain tissue impairment

Growing community of inventors

Kobe, Japan

Yukuo Yoshida